When these original research drugs have passed the patent period in China, other enterprises can imitate their structural formula and imitate similar drugs. Generic drugs can also achieve certain efficacy, if well copied, the efficacy can even be comparable to the original drug. Not only that, generic drugs without R&D process are much cheaper than original drugs. Chen Qun, deputy chief pharmacist of Aviation General Hospital, said that in this way, Chinas limited health insurance fund can afford more patients and the people will take medicine cheaper.
Take bromopizimine in the list as an example. It is the first-line drug for myasthenia gravis. It can alleviate the symptoms of myasthenia gravis. However, at present, only Shanghai Shangyuan Traditional Chinese and Western Pharmaceutical Co., Ltd. produces bromopizimine. Because of the influence of raw materials, technology and environmental protection, some batches of drugs were recalled at one time, resulting in repeated out-of-stock of the drug and higher prices. At present, there is no guarantee of adequate supply in Beijing, let alone in other areas. Chen Qun disclosed that the national introduction of generic drug catalogues to encourage more manufacturers to produce, compete, compress the declaration time, optimize the way of declaration, to a certain extent, to alleviate the supply of such low-cost shortage of drugs, to benefit more patients in urgent need of medication. (Reporter Liu Huan)